window of opportunity elipse trial: elacestrant in postmenopausal women with er her2-/ early bc
Published 1 year ago • 155 plays • Length 2:29Download video MP4
Download video MP3
Similar videos
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
4:06
serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
0:51
ember-2: preoperative imlunestrant for er /her2- early stage breast cancer
-
30:44
what's new for the patient with er /her2- mbc progressing on cdk 4/6 inhibitor therapy? expert pe...
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
2:55
differential long-term benefit of adjuvant tamoxifen in er /her2- premenopausal postmenopausal bc
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
3:27
c2 xplore intraoperative neuromonitoring
-
6:47
how to select treatment for her2 breast cancer patients with brain metastasis?
-
3:00
orserdu tablets how to use: uses, dosage, side effects, contraindications
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
2:06
elacestrant significantly prolongs pfs for er /her2- metastatic bc without prior chemotherapy pts
-
1:05
cambria 1: camizestrant er /her2- early breast cancer
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
1:44
precoopera: giredestrant versus anastrozole in er /her2- early breast cancer
-
3:01
assessing elacestrant in ctdna-positive patients with er breast cancer
-
3:03
elipse clinical trial
-
1:32
elacestrant
-
1:46
phase i/ii study of a novel serca in er her2- bc
-
0:50
op-1250: a small molecule oral complete estrogen receptor antagonist (ceran)